Literature DB >> 16076462

Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor.

Luo Xu1, Inge Depoortere, Pascale Vertongen, Magali Waelbroeck, Patrick Robberecht, Theo L Peeters.   

Abstract

UNLABELLED: The motilin receptor (MTLR) represents a clinically useful pharmacological target, as agonists binding to the MTLR have gastroprokinetic properties. In order to compare the molecular basis for interaction of the MTLR with motilin and with the non-peptide motilin agonist, erythromycin-A (EM-A), the negatively charged E119 located in the third transmembrane (TM3) region was mutated to D (E119D) and Q (E119Q), respectively, and changes in activity of the mutant receptors were verified.
METHODS: Each mutant receptor was stably transfected in CHO-cells containing the Ca2+ indicator apo-aequorin. Receptor activation in response to motilin, EM-A and their analogues was assessed by Ca2+-luminescense.
RESULTS: In the E119Q mutant, the Ca2+ response to motilin and EM-A was abolished while in the E119D mutant it was reduced with 62% (motilin) and 81% (EM-A). The pEC50 values were shifted from 9.65+/-0.03 to 7.41+/-0.09 (motilin) and from 6.63+/-0.12 to 4.60+/-0.07 (EM-A). Acetylation of the N-terminal amine group as in [N-acetyl-Phe]1 mot (1-14), decreased the potency 6.3-fold (WT-MTLR) and 148-fold (E119D). Acetylation of EM-A enol ether induced a more pronounced shift in potency: 7943-fold (WT-MTLR) and 1413-fold (E119D).
CONCLUSION: The comparable loss of affinity of the mutant receptors for motilin and EM-A indicate that these agonists both interact with the TM3 domain of the MTLR. The results with acetylated derivatives support an ionic interaction between E119 of the MTLR with the N+ of the desosamine sugar in EM-A, but not with the N+ of the free amine group in motilin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16076462     DOI: 10.1016/j.bcp.2005.06.022

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Understanding Peptide Binding in Class A G Protein-Coupled Receptors.

Authors:  Irina G Tikhonova; Veronique Gigoux; Daniel Fourmy
Journal:  Mol Pharmacol       Date:  2019-07-10       Impact factor: 4.436

2.  Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro.

Authors:  E M Jarvie; V J North Laidler; S Corcoran; A Bassil; G J Sanger
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

Review 3.  Comparison of Antibiotic Resistance Mechanisms in Antibiotic-Producing and Pathogenic Bacteria.

Authors:  Hiroshi Ogawara
Journal:  Molecules       Date:  2019-09-21       Impact factor: 4.411

4.  Effect of spiramycin and tulathromycin on abomasal emptying rate in milk-fed calves.

Authors:  Mehdi Rashnavadi; Mohammad Nouri; Mohammad R Haji Hajikolaei; Housain Najafzadeh; Peter D Constable
Journal:  Can J Vet Res       Date:  2014-01       Impact factor: 1.310

5.  Expression of motilin in the hypothalamus and the effect of central erythromycin on gastric motility in diabetic rats.

Authors:  Yun-Dan Jia; Chang-Qin Liu; Ming Tang; Zheng-Yao Jiang
Journal:  Neurosci Bull       Date:  2007-03       Impact factor: 5.203

6.  Anxiolytic actions of motilin in the basolateral amygdala.

Authors:  Bin Feng; Jin-Cheng Liu; Jun Zhang; Ken-Ichi Ozaki; Yan-Yan Guo; Ding-Hua Yi; Xiao-Qiang Li; Ming-Gao Zhao
Journal:  Mol Neurobiol       Date:  2013-01-10       Impact factor: 5.590

7.  Berberine Combined with Triple Therapy versus Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Xiaotao Jiang; Chenguang Jiang; Cihui Huang; Guoming Chen; Kailin Jiang; Baoyi Huang; Fengbin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-04       Impact factor: 2.629

Review 8.  Motilin Comparative Study: Structure, Distribution, Receptors, and Gastrointestinal Motility.

Authors:  Takio Kitazawa; Hiroyuki Kaiya
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-23       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.